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Human Adaptive Evolution at Myostatin (GDF8), a Regulator
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Myostatin (GDF8) is a negative regulator of muscle growth in mammals, and loss-of-function mutations are associated
with increased skeletal-muscle mass in mice, cattle, and humans. Here, we show that positive natural selection has acted
on human nucleotide variation at GDF8, since the observed ratio of nonsynonymous:synonymous changes among
humans is signiﬁcantly greater than expected under the neutral model and is strikingly different from patterns observed
across mammalian orders. Furthermore, extended haplotypes around GDF8 suggest that two amino acid variants have
been subject to recent positive selection. Both mutations are rare among non-Africans yet are at frequencies of up to
31% in sub-Saharan Africans. These signatures of selection at the molecular level suggest that human variation at GDF8
is associated with functional differences.
From the Department of Ecology and Evolutionary Biology, University of Arizona, Tucson (M.A.S.; J.M.G.; M.W.N.); Department of Human Genetics,
University of Pittsburgh, Pittsburgh (E.C.L.; R.E.F.); and Department of Ecology and Evolution, University of Chicago, Chicago (M.A.S.; W.-H.L.)
Received July 6, 2006; accepted for publication September 15, 2006; electronically published October 10, 2006.
Address for correspondence and reprints: Dr. Matthew A. Saunders, Department of Ecology and Evolution, University of Chicago, 1101 E. 57th Street,
Chicago, IL 60637. E-mail: saunders@uchicago.edu
Am. J. Hum. Genet. 2006;79:1089–1097.  2006 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7906-0011$15.00
The genetic basis of muscle development and growth has
been extensively studied in an effort to treat myopathies1
and to understand individual variation in athletic per-
formance.2 Because musculature features might have pro-
vided a ﬁtness advantage during human evolution, can-
didate genes related to musculature may have been targets
of natural selection in humans.
The myostatin gene, also called “growth and differen-
tiation factor 8” (GDF8 [MIM 601788]) encodes a negative
regulator of skeletal-muscle growth.3 First described in
the mouse, myostatin is expressed in different muscles
throughout the body, both during early development and
in adults. Mouse null mutants are signiﬁcantly larger than
wild-type animals, with 200%–300%more skeletal-muscle
mass because of an increase in the number of myocytes
(hyperplasy) and an increase in the size of muscle ﬁbers
(hypertrophy).3 A similar phenotype is seen in some breeds
of double-muscled cattle that also have myostatin muta-
tions.4,5 A loss-of-functionmutation in themyostatin gene
(a missplicing change in IVS1:G378A) has been associated
with muscle hypertrophy in a human subject,6 and myo-
statin expression levels have been shown to be inversely
correlated with muscle mass in healthy and HIV-infected
subjects.7 These data suggest that myostatin acts in a sim-
ilar fashion among all mammals. Here, we tested the hy-
pothesis that patterns of human nucleotide variation at
GDF8 have been shaped by positive natural selection.
We resequenced the complete coding sequence ofGDF8,
including partial ﬂanking intron sequences and the 5′ up-
stream cis-promoter region in human panels of 76 African
Americans and 70 Europeans. DNA samples were collected
from residents of Pittsburgh, after receipt of written in-
formed consent. PCR ampliﬁcation primers were designed
to target the entire coding sequence for each GDF8 exon
(I–III) and the putative cis-promoter region for GDF8, lo-
cated ∼500 bp upstream of the ATG start codon.8 DNA se-
quencing was performed on an ABI 3700 automated DNA
sequencer with use of ampliﬁcation oligonucleotides as
primers. (Primers and PCR conditions are available on re-
quest). Sequences were inspected by eye and were aligned
for each individual, with use of the program SEQUEN-
CHER (Gene Codes). The sequence for each individual
was submitted to GenBank under accession numbers
DQ927046–DQ927191.
In the resequenced panels, we detected eight SNPs in
the coding sequence, one indel polymorphism in intron
1, and two SNPs in the 5′ upstream cis-promoter region
(ﬁg. 1A). Surprisingly, nucleotide diversity in the coding
sequence ( ) is four times higher than in thepp 0.038%
noncoding sequence ( ) (table A1). Five of thepp 0.009%
coding SNPs cause nonconservative amino acid replace-
ment changes, whereas the three remaining coding SNPs
cause silent changes (table 1).
Under the neutral model of molecular evolution, the
ratio of replacement:silent changes is expected to be the
same within and between species (McDonald-Kreitman
test).11 To test this null hypothesis for GDF8,we compared
the polymorphism within humans with divergence be-
tween humans and other mammals (table B1). Between
species, we observed many more silent than replacement
mutations, as is typical for most genes. However, within
humans, we observed more replacement than silent mu-
tations, and this difference is statistically signiﬁcant (table
2). This pattern is unusual for human genes and, together
with observations described below, suggests that the high
proportion of amino acid variation in humans is due to
positive natural selection.
To further explore whether the patterns seen at GDF8
1090 The American Journal of Human Genetics Volume 79 December 2006 www.ajhg.org
Figure 1. A, Sequences and number of occurrences of the inferred
haplotypes (A–K) from GDF8 in an African American panel (AFRAM)
and a European panel (EURO). Surveyed regions are P (encom-
passing the putative cis-promoter region), E1, E2, and E3 (span-
ning exons 1, 2, and 3, respectively). Alignment positions are
indicated at the top, relative (in base pairs) to the ATG coding
start position. Polymorphisms in coding regions are shaded. The
consensus sequence is denoted at the top, with sites that cause
replacement polymorphisms shown in bold and silent polymor-
phisms shown in italics. A dot (7) indicates identity to consensus
sequence, and a dash (—) indicates a deletion. Haplotypes bearing
the intermediate frequency replacement changes Ala55Thr and
Lys153Arg (nucleotide alignment positions 163 and 2246, respec-
tively) are shown in bold. Haplotypes of haplogroup 55 and hap-
logroup 153 are indicated by black and gray ovals, respectively.
B, Haplotype tree for GDF8. Each circle represents an inferred hap-
lotype (A–K) in a size proportional to the haplotype frequency in
the combined sample (AFRAM and EURO). Hatch marks represent
single mutations labeled according to the alignment positions in
panel A. Positions of replacement changes are indicated in bold-
face numbers. Replacement changes at amino acid sites 55 and
153 (alignment positions 163 and 2246, respectively) are boxed.
Positions of silent changes are italicized. Haplotypes of haplogroup
55 and haplogroup 153 are indicated by black and gray circles,
respectively. The haplotype inference method9 is known to be in-
accurate for rare ( ) frequency polymorphisms. Mutationsq ! 0.01
307 and 5273 are both at low frequency in the sample (qp
) and therefore may have been incorrectly assigned to a0.0068
haplotype with mutation 2246. Alternative haplotype inferences
for individual AFRAM_B11 would be (C,Y) (HapY: AGFGCGCAF—
FTAFT) and, for individual EURO_B08, would be (C,Z) (HapZ:
AGFGCGCGFAFTAFC) (see panel A and ﬁg. A1).







A55T* I GCCrACC 163 .118 .007
60I I ATCrATT 180 .020 .000
R65H I CGTrCAT 194 .013 .000
102S I AGCrAGT 306 .020 .000
D103N I GATrAAT 307 .007 .000
M129R II ATGrAGG 2174 .020 .000
K153R* II AAGrAGG 2246 .197 .036
E164K* II GAGrAAG 2278 NA NA
P198A* II CCArGCA 2380 NA NA
I225T* II ATTrACT 2462 NA NA
354N III AATrAAC 5273 .000 .007
NOTE.—Alleles marked in italics are synonymous changes;
all others are nonsynonymous changes. NAp not applicable.
a Substitutions marked with an asterisk (*) denote poly-
morphisms identiﬁed previously.10 Substitutions E164K, P198A,
and I225T were not detected in our current samples.
b The polymorphic nucleotide for each codon is shown in
bold.
c Position is denoted as distance (in bp) from the ﬁrst
nucleotide of the start codon (relative to the consensus human
sequence).
in humans are unexpected, we comparedGDF8 sequences,
obtained from public databases, among mammals and
other vertebrates. We estimated the average ratio of re-
placement:silent substitutions per site (dN:dS) across 15
mammalian lineages, using maximum likelihood12 (table
B1). In the absence of functional constraint, the nonsy-
nonymous substitution rate (dN) is expected to be equal
to the synonymous substitution rate (dS), whereas d :d !N S
is indicative of purifying selection. The average dN:dS1
ratio across the mammalian phylogeny is 0.10, which sug-
gests thatGDF8 has been under strong constraint through-
out much of mammalian evolution. Furthermore, most
pairwise interspeciﬁc comparisons with humans show even
higher levels of constraint. For example, between mouse
and human for GDF8, well below themediand :d p 0.05N S
genomewide value of 0.12.13 Thus, the pattern of ﬁve re-
placement and three silent changes within humans stands
out as being exceptional.
Next, we looked at the amino acid sites of each of the
ﬁve human replacement polymorphisms across all verte-
brate species with available GDF8 sequences (a total of 20
species, including ﬁsh, birds, and mammals [table B1]).
The ﬁve sites that are polymorphic in humans are remark-
ably conserved over evolutionary timescales. The ances-
tral amino acid states associated with the alleles Ala55Thr
(G163A), Arg65His (G194A), and Asp103Asn (G307A) are
conserved among all vertebrates; Lys153Arg (A2246G) is
conserved among all taxa except ﬁsh (Danio rerio), and
Met129Arg (T2174G) is conserved among all mammals
except bovines. This high level of conservation for indi-
vidual residues suggests that the mutations in humans
have functional consequences.
To learn more about patterns of evolution at GDF8
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Macaque 8 1 !.05
Mouse 77 15 !.01
Rat 86 17 !.01
Dog 77 15 !.01
NOTE.—Results of a 2#2 Fisher’s exact test of inde-
pendence between the human polymorphism found in the
current study and divergence (ﬁxed differences) from ma-
caque, mouse, rat, and dog GDF8 sequences. Three ad-
ditional replacement polymorphisms at GDF8 have been
reported in a different sample of humans,10 which brings
the total number of known GDF8 replacement polymor-
phisms to 8 (table 1), in which case Fisher’s exact test
results are and relative to macaque andP ! .01 P ! .001
the other mammals, respectively.
Figure 2. A, EHH at varying genetic distances from the core
regions that include A2246G and G163A at GDF8. The EHH for each
haplotype at a frequency 17% is displayed as follows. The core
haplotypes of haplogroups 153 and 55 are indicated by a solid
gray line and a solid black line, respectively. These extended hap-
lotypes exhibit high levels of EHH at a distance of up to 0.2 cM
from the core. All other core haplotypes are indicated by dashed
lines. B, EHH relative to population frequency. EHH values were
calculated for each core haplotype at a genetic distance of 0.2
cM. An empirical distribution of EHH values was produced for core
haplotypes from 10 anonymous genomic regions across chromo-
some 2 in the HapMap YRI panel. These data were compared with
core haplotypes from the genomic region spanning ∼300 kb cen-
tered on GDF8. Values of EHH for the GDF8 core haplotypes rep-
resenting haplogroups 153 (gray arrow) and 55 (black arrow) are
signiﬁcantly higher than other core haplotypes within the same
population frequency bin ( and , respectively).Pp .01 Pp .03
in humans, we inferred haplotype phase for the diploid
sequences.9 The two intermediate frequency polymor-
phisms—Ala55Thr and Lys153Arg (nucleotide mutations
163 and 2246, respectively)—reside on separate haplotypes
(ﬁg. 1A). The mutation at site 163 is associated with two
haplotypes: A and K (referred to as “haplogroup 55”) (ﬁg.
1A). Haplotype K bears a derived mutation in the GDF8
promoter region (site 762) that is found exclusively in
association with the nonsynonymous change at site 163.
The mutation at site 2246 is associated with six different
haplotypes (haplotypes C, D, F, G, H, and J; referred to as
“haplogroup 153”). Interestingly, all the low-frequency re-
placement mutations appear to be in association with a
haplotype bearing the 2246 mutation (ﬁg. 1B). We esti-
mated the age of the mutations 2246 and 163, using long-
range linked-polymorphism data (see YRI HapMap data
below). The age estimates suggest that both alleles are rel-
atively young and arose within the past 10,000 years (ap-
pendix C).
Alleles that have experienced recent positive selection
may bear a signature of unusually long-range linkage dis-
equilibrium with surrounding SNPs.15,16 To test for this pat-
tern at GDF8, we examined the SNP data from the Inter-
national HapMap Project17 in the genomic region of GDF8.
Both sites G163A and A2246G have been genotyped in
the International HapMap Project (SNPs rs1805085 and
rs1805086, respectively), and the minor-allele frequency
for both SNPs in the Yoruban (YRI) panel from Ibadan,
Nigeria, is 22%. We retrieved phased haplotypes spanning
300 kb roughly centered on GDF8 from the International
HapMap Project (human genome build 16) for 60 indi-
viduals from the YRI panel. We similarly retrieved phased
SNP data from the YRI panel at 10 additional anonymous
genomic regions, each spanning ∼300 kb from across chro-
mosome 2. Nonoverlapping core haplotypes (restricted to
a maximum size of 8 contiguous SNPs) were deﬁned in
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Figure 3. Population frequencies for GDF8 replacement nucleotide polymorphisms G163A and A2246G (corresponding to haplogroups
55 and 153, respectively) in a worldwide panel (HGDP-CEPH Diversity Panel). For each population, the respective pie chart denotes the
frequencies of haplogroups 55 (dark shading) and 153 (light shading). Population and haplogroup details are shown in table 3.
each genomic region, and extended haplotype homozy-
gosity (EHH) was calculated at increasing genetic distances
(measured in centimorgans).15 We used the cores of the
anonymous regions to generate an empirical distribution
for the relationship between EHH and haplotype fre-
quency. Statistical signiﬁcance for departure of an EHH
value within a frequency bin was determined for given
GDF8 haplotypes relative to the empirical distribution
data. All long-range haplotype analyses were conducted
using SWEEP software, according to standard documen-
tation.15 Using these data, we determined that the long-
range haplotypes associated with haplogroups 153 and 55
exhibit a signiﬁcant level of EHH relative to other core
haplotypes up to ∼0.2 cM away from GDF8 (ﬁg. 2A) and
relative to an empirical distribution of core haplotypes
from other genomic loci (ﬁg. 2B) ( and forPp .01 Pp .03
haplogroups 153 and 55, respectively). It is noteworthy
that a recent genomic scan for positive selection in the
human genome that was based on a modiﬁcation of the
EHH statistic (i.e., the integrated haplotype score [IHS])
failed to identify long-range haplotypes in the genomic
region of GDF8 as extreme (top 1%) outliers.14 However,
this method (the IHS statistic) lacks power to detect se-
lection on derived haplotypes at population frequencies
! 0.5,14 as is the case for GDF8 and some other loci known
to be under selection (e.g., G6PD [MIM 305900]).
Interestingly, two replacement polymorphisms—G163A
and A2246G (representing haplogroups 55 and 153, re-
spectively)—are at relatively high frequency among Afri-
can Americans (12% and 20%, respectively) and the YRI
panel (22% each) but are at much lower frequencies among
the Europeans sampled here (1% and 4%, respectively)
(table 1) and in the HapMap panels from Europe (0% and
2%, respectively) and Asia (0% each). Furthermore, it is
notable that 150% (39 of 76) of the African Americans and
75% (45 of 60) of the YRI individuals bear at least one of
these replacement alleles (ﬁgs. 1A and A1). To have amore
complete view of the frequencies of G163A and A2246G
in human populations, we genotyped 1,040 individuals
in a worldwide panel that included samples from Africa,
Europe, Asia, and the Americas (HumanGenomeDiversity
Project [HGDP]–CEPH Diversity Panel).18 SNP genotyping
of this global panel was performed using TaqMan Assays
by Design (Applied Biosystems). A separate assay probe
was designed for each of the polymorphisms (G163A and
A2246G), and reactions were performed, following man-
ufacturer’s protocols, on an ABI 7500 Real-Time PCR ma-
chine. All homozygotes of the rare alleles and any am-
biguous calls were conﬁrmed by PCR and direct resequenc-
ing. Results of the global survey show that one or both of
mutations G163A or A2246G are found in populations of
sub-Saharan Africa at a frequency 114%, whereas, in non-
African populations, their frequencies are typically absent
and only rarely exceed 5% (ﬁg. 3 and table 3).
The signature of positive selection at themolecular level
in humans is often weak, in part because of the relatively
small long-term effective population size and low levels
of standing variation. As a result, recent studies have fo-
cused onmethods to detect selection on the basis of subtle
aspects of the data, such as the decay of long-range linkage
disequilibrium around a target of selection.14,15,19 In con-
trast, the results presented here for GDF8 also reveal a
strong signature of positive selection that is based on an
excess of nonsynonymous polymorphism, as previously
seen only for a few other genes in humans (e.g., G6PD
and the major histocompatibility complex).20,21 An earlier
survey of human variation at GDF8 revealed three addi-
tional low-frequency replacement polymorphisms (but no
additional silent polymorphisms) that were not detected
in our current resequenced panels,10 which increases to
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Table 3. Population and Haplogroup Details for Figure 3
Map






1a Bantu NE Kenya 12 29 25
1b Bantu SW South Africa 8 6 31
2 Mandenka Senegal 23 24 20
3 Yoruba Nigeria 24 8 19
4 San Namidia 7 0 14
5 Mbuti Pygmies Democratic Republic of Congo 14 4 29
6 Biaka Pygmies Central African Republic 36 8 14
7 Mozabite Algeria (Mzab) 29 2 2
8 Orcadian Scotland (Orkney Islands) 15 0 3
9 Adygei Russia (Caucasus) 17 0 3
10 Russian Russia 25 0 0
11 French Basque France 24 0 4
12 French France 27 0 2
13 North Italian Italy (Bergamo) 14 0 0
14 Sardinian Italy 28 0 7
15 Tuscan Italy 8 0 6
16 Bedouin Israel (Negev) 48 0 5
17 Druze Israel (Carmel) 47 0 1
18 Palestinian Israel (Central) 49 1 9
19 Balochi Pakistan 25 0 4
20 Brahui Pakistan 25 2 2
21 Makrani Pakistan 25 0 12
22 Sindhi Pakistan 25 0 4
23 Pathan Pakistan 24 2 0
24 Burusho Pakistan 25 0 4
25 Hazara Pakistan 22 0 0
26 Uygur China 9 0 0
27 Kalash Pakistan 25 0 0
29 Han China 43 0 1
30 Dai China 10 0 0
31 Daur China 10 0 0
32 Hezhen China 10 0 0
33 Lahu China 10 0 0
34 Miaozu China 10 0 0
35 Oroqen China 10 0 0
36 She China 10 0 0
37 Tujia China 8 0 0
38 Tu China 10 0 0
39 Xibo China 9 0 0
40 Yizu China 10 0 0
41 Mongolian China 10 0 5
42 Naxi China 10 0 0
43 Cambodian Cambodia 10 0 0
44 Japanese Japan 30 0 0
45 Yakut Russia (Siberia) 24 0 2
46 Melanesian Bougainville 22 0 0
47 Papuan New Guinea 17 0 0
48 Karitiana Brazil 24 0 0
49 Surui Brazil 21 0 0
50 Colombian Colombia 13 0 0
51 Maya Mexico 24 0 0
52 Pima Mexico 25 0 0
eight the total number of replacement changes at GDF8
that have been reported to date (table 1) and contributes
further to the observed excess of replacement polymor-
phisms among humans.
Although positive selection may increase the level of
polymorphismat a locus, the excess of replacementchanges
seen at GDF8 could, in principle, alternatively be explained
either by a recent relaxation of selective constraint or by
the presence of slightly deleterious variants among hu-
mans.22,23 However, both of these explanations seem un-
likely for GDF8. Relaxed selection at GDF8 is improbable,
in view of the overall strong conservation of this gene
over deep evolutionary timescales and the major phe-
notypic effect associated with loss of function in humans.6
1094 The American Journal of Human Genetics Volume 79 December 2006 www.ajhg.org
The two major replacement variants at GDF8 are unlikely
to be slightly deleterious, because these are at relatively
high frequency (up to 31%) in sub-Saharan Africans.More-
over, the atypical long-range haplotype conservation as-
sociated with haplogroups 153 and 55 suggests that these
variants have rapidly increased in frequency. Although
demographic processes associated with population bottle-
necks and expansions may create long-range haplotype
patterns that mimic a signature of selection,24 this is not
likely to be the case at myostatin, since the signature of
selection is seen in the ancestral African population. To-
gether, these data argue that some form of recent diver-
sifying selection has played a signiﬁcant role in shaping
patterns of variation at GDF8.
Themolecular positions of polymorphic residues 55 and
153 within the human GDF8 peptide allow us to speculate
about the phenotypic consequences of these variants. Both
residues are found within the propeptide region (residues
1–266) of GDF8. As is characteristic of other members of
the transforming growth factor beta (TGF-b) superfamily,
the GDF8 precursor peptide is cleaved into an (N-termi-
nus) propeptide and a (C-terminus) mature peptide. The
active form of myostatin is a homodimer of the mature
peptide, which binds to extracellular activin type II recep-
tors (ACTRIIB [MIM 602730]) to induce intracellular ac-
tivation of SMAD proteins.25 Importantly, the propeptide
of GDF8 binds to the mature homodimer to form a latent
myostatin complex and thus regulates GDF8 activity by
preventing the homodimer from binding to its target re-
ceptors.26 Concordantly, overexpression of GDF8 propep-
tide in transgenic mice causes muscle hypertrophy and
hyperplasia similar to that in GDF8-nullmutants.26,27More-
over, intraperitoneal administration of myostatin propep-
tide to Mdx mice (models for Duchenne muscular dys-
trophy) has been shown to rescue some of the muscular
pathophysiological effects found in this mutant.28 Inter-
estingly, residue 55 is within a major inhibitory domain
of the GDF8 propeptide (residues 42–115)29 and therefore
may inﬂuence the regulatory properties of the propeptide.
In general, any mutations that increase the binding afﬁn-
ity between the propeptide and the mature peptide could
generate a relative deﬁciency of myostatin activity. One
of the many possible adaptive implications of such an
effect could be protection from muscle wasting in times
of famine, a potentially recurrent phenomenon for early
agricultural societies.30
The evidence of positive selection on GDF8 in humans
implies that some of the replacement changes cause phe-
notypic changes related to muscle development and/or
growth. Laboratory studies that measured human adult
muscle response after short-term physical training failed
to detect associations between increased muscle mass and
several common amino acid polymorphisms.10 However,
the potential phenotypic effect on preadult muscle devel-
opment remains unknown. Also, natural selectionmay act
on ﬁtness differences that are subtle and not easily de-
tected in laboratory settings. A separate evolutionary anal-
ysis has shown accelerated evolution at GDF8 along three
bovid lineages in the propeptide region of GDF8, which
demonstrates that GDF8 has been a target of selection
along another branch inmammalian evolution.31Although
the phenotypic target of selection remains elusive in hu-
mans, transgenic mouse models and functional assays
may facilitate the quantiﬁcation of speciﬁc traits associ-
ated with the GDF8 replacement changes identiﬁed here.
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Appendix A
Figure A1. Table of polymorphism for diploid data for GDF8. The
legend is available in its entirety in the online edition of The
American Journal of Human Genetics.
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Nonsynonymous Synonymous vp vW Homo-Pan Homo-Pongo
Africa ( ):np 76
Coding 7 5 2 .061 (.007) .111 (.048) .9963 .2388
Noncoding 2 NA NA .015 (.004) .036 (.026) .8283 .6547
Total 9 5 2 .040 (.040) .076 (.030) 1.3124 .4935
Europe ( ):np 70
Coding 3 2 1 .009 (.003) .048 (.029) 1.3887 2.1189
Noncoding 1 NA NA .001 (.001) .018 (.018) .9906 2.1156
Total 4 2 1 .005 (.002) .034 (.018) 1.5858 2.8351c
Combined ( )Np 146
Coding 8 5 3 .038 (.004) .114 (.046) 1.4116 .6140 .198 .717
Noncoding 2 NA NA .009 (.002) .032 (.023) .9427 .6140 .813 2.060
Total 10 5 3 .024 (.003) .076 (.028) 1.5237 .3207 .486 1.345
NOTE.—A total of 2,114 (1,125 coding; 989 noncoding) base pairs were analyzed. NA p not applicable.
a The noncoding sequence includes the surveyed region P (which includes the GDF8 promoter region) and the intron sequence ﬂanking the exons
in the surveyed regions.
b Divergence estimates are based on the average of all pairwise comparisons between the human samples and respective outgroup samples
(GenBank accession numbers DQ927199–DQ927203 and DQ927192–DQ927194).
c .P ! .05
Appendix B
Table B1. Silent and Replacement Changes at GDF8, Relative to the Homo sapiens
Consensus Sequence
Species Common Name Accession Numbera
No. of Changes
dN :dSSilent Replacement
Homo sapiens Human NM_005259 3 5 .663
Pan troglodytes Common chimpanzee ENSPTRT00000023612b 1 1 .267
Pan paniscus Pygmy chimpanzee DQ927196c 1 1 .267
Gorilla gorilla Gorilla DQ927204c 1 1 .267
Pongo pygmeus Orangutan DQ927192c 6 1 .045
Papio hamadryas Baboon AF019619 7 2 .096
Macaca mulatta Rhesus macaque DQ927195c 4 1 .085
Macaca fascicularis Crab-eating macaque AY055750 8 1 .035
Mus musculus Mouse NM_010834 77 15 .051
Rattus norvegicus Rat NM_019151 86 17 .055
Canis familiaris Dog AY367768 77 15 .060
Vulpes vulpes Red fox AY647144 81 16 .058
Alopex lagopus Arctic fox AY606017 81 16 .058
Sus scrofa Pig AF019623 42 8 .056
Bos taurus Cow NM_001001525 69 23 .099
Bubalis bubalis Water buffalo AH013313 64 28 .130
Ovis aries Sheep AF019622 59 25 .128
Capra hircus Goat AY436347 60 27 .134
Equus caballus Horse AB033541 38 9 .072
Meleagris gallopavo Turkey AF019625 131 31 .050
Gallus gallus Chicken ENSGALT00000003669b 136 31 .049
Coturnix coturnix Common quail AF407340 130 33 .055
Coturnix chinensis Painted Chinese quail AF440864 130 33 .056
Danio rerio Zebraﬁsh ENSDART00000001757b 233 159 .031
NOTE.—Bold text for the human data indicates polymorphisms.
a All are GenBank accession numbers unless otherwise noted.
b Ensembl accession number.
c Sequence generated for the current study.
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Appendix C
Estimation of the Ages of Selected Alleles
We employed an approach described elsewhere14 to
roughly estimate the ages of mutations 163 and 2246 (rep-
resenting alleles Ala55Thr and Lys153Arg, respectively).
Long-range haplotypes, from the HapMap data, around
GDF8 in the YRI panel were used to calculate the EHH
statistic (see the text and ﬁg. 2A). By deﬁnition, EHH ≈
, where Pr(Homozygosity) is the2rgPr (Homozygosity)p e
probability that two chromosomes are homozygous at re-
combination distance r from the core, given identity by
decent from a common ancestor g generations ago. With
use of a generation time of 25 years for humans, ,gp t/25
where t is time in years.
For the core haplotype bearing mutation 163,
2r ≈ 0.265% and Pr [Homozygosity] p 0.35 ,
so
(25)(100) ln (0.35)
tp ≈ 10,000 years ,
0.265
and, for the core haplotype-bearing mutation 2246,
2r ≈ 0.246% and Pr (Homozygosity)p 0.45 ,
so
(25)(100) ln (0.45)
tp ≈ 8,000 years .
0.246
These estimates are crude, since the theoretical models
for estimating ages of multiple alleles under selection in
a population are not well developed. The current method
assumes a starlike genealogy for the selected haplotypes;
therefore, these results are likely underestimates of the true
ages of the alleles.
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
Ensembl, http://www.ensembl.org/
GenBank, http://www.ncbi.nih.gov/Genbank/ (for GDF8 [acces-
sion numbers DQ927046–DQ927191], P. troglodytes [accession
numbers DQ927199–DQ927203],H. sapiens [accession number
NM_005259], P. paniscus [accession number DQ927196], G. go-
rilla [accession number DQ927204], P. pygmeus [accessionnum-
bers DQ927192–DQ927194], P. hamadryas [accession number
AF019619], M. mulatta [accession number AY055750], M. mus-
culus [accession number NM_010834], R. norvegicus [acces-
sion number NM_019151], C. familiaris [accession number
AY367768], V. vulpes [accession number AY647144], A. lagopus
[accession number AY606017], S. scrofa [accession number
AF019623], B. taurus [accession number NM_001001525], B.
bubalis [accession number AH013313], O. aries [accession num-
ber AF019622], C. hircus [accession number AY436347], E. ca-
ballus [accession number AB033541], M. gallopavo [accession
number AF019625], C. coturnix [accession number AF407340],
and C. chinensis [accession number AF440864])
International HapMap Project, http://www.hapmap.org/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for GDF8, G6PD, and ACTRIIB)
SWEEP, http://www.broad.mit.edu/mpg/sweep/download.html
References
1. Gordon ES, Dressman HAG, Hoffman EP (2005) The genetics
of muscle atrophy and growth: the impact and implications
of polymorphisms in animals and humans. Int J Biochem
Cell Biol 37:2064–2074
2. Thomis MAI, Huygens W, Heuninckx S, Chagnon M, Maes
HHM, Claessens AL, Vlietinck R, Bouchard C, Beunen GP
(2004) Exploration of myostatin polymorphisms and the an-
giotensin-converting enzyme insertion/deletion genotype in
responses of human muscle to strength training. Eur J Appl
Physiol 92:267–274
3. McPherron AC, Lawler AM, Lee SJ (1997) Regulation of skel-
etal muscle mass in mice by a new TGF-b superfamily mem-
ber. Nature 387:83–90
4. McPherron AC, Lee SJ (1997) Double muscling in cattle due
to mutations in the myostatin gene. Proc Natl Acad Sci USA
94:12457–12461
5. Kambadur R, Sharma M, Smith TPL, Bass JJ (1997) Mutations
in myostatin (GDF8) in double-muscled Belgian blue and Pied-
montese cattle. Genome Res 7:910–916
6. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen
W, Braun T, Tobin JF, Lee SJ (2004) Myostatin mutation as-
sociated with gross muscle hypertrophy in a child. N Engl J
Med 350:2682–2688
7. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim
I, Ma K, Ezzat S, Shen RQ, Lalani R, Asa S, Mamita M, Nair
G, Arver S, Bhasin S (1998) Organization of the humanmyo-
statin gene and expression in healthy men and HIV-infected
men with muscle wasting. Proc Natl Acad Sci USA 95:14938–
14943
8. Ma K, Mallidis C, Artaza J, Taylor W, Gonzalez-Cadavid N,
Bhasin S (2001) Characterization of 5′-regulatory region of
human myostatin gene: regulation by dexamethasone in vi-
tro. Am J Physiol Endocrinol Metab 281:E1128–E1136
9. Stephens M, Smith NJ, Donnelly P (2001) A new statistical
method for haplotype reconstruction from population data.
Am J Hum Genet 68:978–989
10. Ferrell RE, Conte V, Lawrence EC, Roth SM, Hagberg JM, Hur-
ley BF (1999) Frequent sequence variation in the humanmyo-
statin (GDF8) gene as a marker for analysis of muscle-related
phenotypes. Genomics 62:203–207
11. McDonald JH, KreitmanM (1991) Adaptive protein evolution
at the adh locus in Drosophila. Nature 351:652–654
12. Yang ZH (1997) PAML: a program package for phylogenetic
analysis by maximum likelihood. Comput Appl Biosci 13:555–
556
13. Mouse Genome Sequencing Consortium (2002) Initial se-
quencing and comparative analysis of the mouse genome.
Nature 420:520–562
14. Voight BF, Kudaravalli S, Wen XQ, Pritchard JK (2006) A map
of recent positive selection in the human genome. PloS Biol
4:446–458
www.ajhg.org The American Journal of Human Genetics Volume 79 December 2006 1097
15. Sabeti PC, Reich DE, Higgins JM, Levine HZP, Richter DJ,
Schaffner SF, Gabriel SB, Platko JV, Patterson NJ, McDonald
GJ, Ackerman HC, Campbell SJ, Altshuler D, Cooper R, Kwiat-
kowski D, Ward R, Lander ES (2002) Detecting recent positive
selection in the human genome from haplotype structure.
Nature 419:832–837
16. Saunders MA, Slatkin M, Garner C, Hammer MF, Nachman
MW (2005) The extent of linkage disequilibrium caused by
selection on G6PD in humans. Genetics 171:1219–1229
17. International HapMap Consortium (2005) A haplotype map
of the human genome. Nature 437:1299–1320
18. Cavalli-Sforza LL (2005) The Human Genome Diversity Pro-
ject: past, present and future. Nat Rev Genet 6:333–340
19. Toomajian C, Ajioka RS, Jorde LB, Kushner JP, Kreitman M
(2003) A method for detecting recent selection in the human
genome from allele age estimates. Genetics 165:287–297
20. Verrelli BC, McDonald JH, Argyropoulos G, Destrol-Bisol G,
Froment A, Drousiotou A, Lefranc G, Helal AN, Loiselet J,
Tishkoff SA (2002) Evidence for balancing selection from nu-
cleotide sequence analyses of humanG6PD. Am JHumGenet
71:1112–1128
21. Hughes AL, Nei M (1989) Nucleotide substitution at major
histocompatibility complex class-II loci: evidence for over-
dominant selection. Proc Natl Acad Sci USA 86:958–962
22. Bustamante CD, Fledel-Alon A, Williamson S, Nielsen R, Hu-
bisz MT, Glanowski S, Tanenbaum DM, White TJ, Sninsky JJ,
Hernandez RD, Civello D, Adams MD, Cargill M, Clark AG
(2005) Natural selection on protein-coding genes in the hu-
man genome. Nature 437:1153–1157
23. Chimpanzee Sequencing and Analysis Consortium (2005)
Initial sequence of the chimpanzee genome and comparison
with the human genome. Nature 437:69–87
24. Currat M, Excofﬁer L, Maddison W, Otto SP, Ray N, Whitlock
MC, Yeaman S (2006) Comment on “Ongoing adaptive evo-
lution of ASPM, a brain size determinant in Homo sapiens”
and “Microcephalin, a gene regulating brain size, continues to
evolve adaptively in humans.” Science 313:172
25. Yingling JM, Blanchard KL, Sawyer JS (2004) Development
of TGF-b signaling inhibitors for cancer therapy.Nat RevDrug
Discov 3:1011–1022
26. Lee SJ, McPherron AC (2001) Regulation ofmyostatin activity
and muscle growth. Proc Natl Acad Sci USA 98:9306–9311
27. Yang JZ, Ratovitski T, Brady JP, Solomon MB, Wells KD, Wall
RJ (2001) Expression of myostatin pro domain results inmus-
cular transgenic mice. Mol Reprod Dev 60:351–361
28. Bogdanovich S, Perkins KJ, Krag TOB, Whittemore SA, Khur-
ana TS (2005) Myostatin propeptide-mediated amelioration
of dystrophic pathophysiology. FASEB J 19:543–549
29. Jiang MS, Liang LF, Wang SS, Ratovitski T, Holmstrom J, Bar-
ker C, Stotish R (2004) Characterization and identiﬁcation of
the inhibitory domain of GDF-8 propeptide. Biochem Bio-
phys Res Commun 315:525–531
30. Wells JCK (2006) The evolution of human fatness and sus-
ceptibility to obesity: an ethological approach. Biol Rev 81:
183–205
31. Tellgren A, Berglund AC, Savolainen P, Janis CM, Liberles DA
(2004) Myostatin rapid sequence evolution in ruminants pre-
dates domestication. Mol Phylogenet Evol 33:782–790
